- Home
- MGIC vs GYRE Comparison
MGIC vs GYRE Comparison
Compare MGIC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- GYRE
- Stock Information
- Founded
- MGIC 1983
- GYRE 2002
- Country
- MGIC Israel
- GYRE United States
- Employees
- MGIC N/A
- GYRE N/A
- Industry
- MGIC Computer Software: Prepackaged Software
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- MGIC Technology
- GYRE Health Care
- Exchange
- MGIC Nasdaq
- GYRE Nasdaq
- Market Cap
- MGIC 788.0M
- GYRE 897.1M
- IPO Year
- MGIC 1991
- GYRE N/A
- Fundamental
- Price
- MGIC $21.41
- GYRE $7.64
- Analyst Decision
- MGIC Buy
- GYRE
- Analyst Count
- MGIC 2
- GYRE 0
- Target Price
- MGIC $16.00
- GYRE N/A
- AVG Volume (30 Days)
- MGIC 82.2K
- GYRE 153.7K
- Earning Date
- MGIC 08-13-2025
- GYRE 08-12-2025
- Dividend Yield
- MGIC 2.63%
- GYRE N/A
- EPS Growth
- MGIC 1.33
- GYRE N/A
- EPS
- MGIC 0.76
- GYRE 0.02
- Revenue
- MGIC $569,136,000.00
- GYRE $100,643,000.00
- Revenue This Year
- MGIC $10.52
- GYRE $21.04
- Revenue Next Year
- MGIC $6.01
- GYRE $89.64
- P/E Ratio
- MGIC $28.24
- GYRE $93.27
- Revenue Growth
- MGIC 6.37
- GYRE N/A
- 52 Week Low
- MGIC $9.64
- GYRE $6.11
- 52 Week High
- MGIC $22.00
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- MGIC 69.61
- GYRE 48.87
- Support Level
- MGIC $20.52
- GYRE $7.09
- Resistance Level
- MGIC $21.79
- GYRE $7.62
- Average True Range (ATR)
- MGIC 0.50
- GYRE 0.37
- MACD
- MGIC -0.12
- GYRE 0.05
- Stochastic Oscillator
- MGIC 67.76
- GYRE 48.72
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.